Early-stage Focus Target opportunities with small biotech and pharma startups; Azevan is a low-employee, small-revenue company likely seeking cost-effective partnerships, licensing, or contract research services to advance their SRX246 program.

Clinical Pipeline Azevan is developing SRX246 for neuropsychiatric symptoms in Huntington's disease, indicating a potential need for CRO support, specialized assay development, biomarker services, and regulatory guidance to progress preclinical to clinical stages.

Funding Signals With modest funding and revenue under $1M, there may be budget constraints; position cost-efficient, milestone-based collaborations, and value-driven packages that maximize ROI and minimize upfront costs.

Technology Synergy Their tech stack includes web and development tools; explore partnerships that leverage digital health data, secure collaboration platforms, and compliant data management to support research and IP protection.

Global Expansion Headquartered in China with limited size suggests potential for international collaboration; offer global CRO networks, multiregional trial support, and regulatory navigation to help reach broader markets.